Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Trial Profile

A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs CS-1003 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors CStone Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03809767)
    • 18 Nov 2018 According to a CStone Pharmaceuticals media release,Status changed from planning to recruiting.
    • 18 Nov 2018 According to a CStone Pharmaceuticals media release, first patient dosed in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top